BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
102 results:

  • 1. "Examining the link between tooth agenesis and papillary thyroid cancer: is there a risk factor?" Observational study.
    Matošić Ž; Šimunović L; Jukić T; Granić R; Meštrović S
    Prog Orthod; 2024 Mar; 25(1):12. PubMed ID: 38523193
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.
    Feng S; Ding B; Dai Z; Yin H; Ding Y; Liu S; Zhang K; Lin H; Xiao Z; Shen Y
    J Transl Med; 2024 Mar; 22(1):280. PubMed ID: 38491511
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Alteration of chromosome structure impacts gene expressions implicated in pancreatic ductal adenocarcinoma cells.
    Han W; Shi D; Yang Q; Li X; Zhang J; Peng C; Yan F
    BMC Genomics; 2024 Feb; 25(1):206. PubMed ID: 38395755
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
    Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
    J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.
    Heublein S; Pfisterer J; du Bois A; Anglesio M; Aminossadati B; Bhatti I; Sehouli J; Wimberger P; Schochter F; Hilpert F; Hillemanns P; Kalder M; Schroeder W; Mahner S; Burges A; Canzler U; Gropp-Meier M; Jackisch C; Harter P; Kommoss S; Marmé F
    Lab Invest; 2024 Apr; 104(4):100321. PubMed ID: 38154497
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
    Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
    Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
    Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
    JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer.
    Lin Q; Serratore A; Perri J; Roy Chaudhuri T; Qu J; Ma WW; Kandel ES; Straubinger RM
    Br J Pharmacol; 2024 May; 181(9):1383-1403. PubMed ID: 37994108
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
    Vera R; Ibarrola-de Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
    Rev Esp Patol; 2023; 56(1):32-44. PubMed ID: 36599598
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Exceptional Response to Erdafitinib in fgfr2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.
    Ng CF; Glaspy J; Placencio-Hickok VR; Thomassian S; Gong J; Osipov A; Hendifar AE; Moshayedi N
    J Natl Compr Canc Netw; 2022 Oct; 20(10):1076-1079. PubMed ID: 36240849
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
    Vera R; Ibarrola-de-Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
    Clin Transl Oncol; 2022 Nov; 24(11):2107-2119. PubMed ID: 36008616
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Endometrial, Ovarian, and Peritoneal Involvement by Endometrioid Carcinoma, Yolk Sac Tumor, and Endometriosis: Molecular Evidence for a Shared Precursor.
    Halling GC; Udager AM; Skala SL
    Int J Gynecol Pathol; 2023 May; 42(3):247-253. PubMed ID: 35639393
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Intraductal tubulopapillary neoplasm (ITPN) of the pancreas: a distinct entity among pancreatic tumors.
    Paolino G; Esposito I; Hong SM; Basturk O; Mattiolo P; Kaneko T; Veronese N; Scarpa A; Adsay V; Luchini C
    Histopathology; 2022 Sep; 81(3):297-309. PubMed ID: 35583805
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The Molecular Landscape of Pancreatobiliary cancers for Novel Targeted Therapies From Real-World Genomic Profiling.
    Umemoto K; Yamamoto H; Oikawa R; Takeda H; Doi A; Horie Y; Arai H; Ogura T; Mizukami T; Izawa N; Moore JA; Sokol ES; Sunakawa Y
    J Natl Cancer Inst; 2022 Sep; 114(9):1279-1286. PubMed ID: 35583261
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Mucinous Tumor Coexisting With Mesonephric-like Proliferation/Tumor in the Ovary: A Novel Association.
    Nilforoushan N; Liu L; Cheang G; Sui AC; Andersen J; Finkelman BS; Liu Y; Nasseri-Nik N; Vang R; Ronnett BM; Song W; Xing D
    Am J Surg Pathol; 2022 Aug; 46(8):1095-1105. PubMed ID: 35405716
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
    Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
    Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing.
    Huang CC; Liu CY; Huang CJ; Hsu YC; Lien HH; Wong JU; Tai FC; Ku WH; Hung CF; Lin JT; Huang CS; Chiang HS
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163506
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Stage 4 pancreatic adenocarcinoma harbouring an
    Poon D; Tan MH; Khor D
    BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34511423
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/fgfr2 promotes invasion and metastasis of pancreatic cancer.
    Zhang Z; Qin Y; Ji S; Xu W; Liu M; Hu Q; Ye Z; Fan G; Yu X; Liu W; Xu X
    Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(8):997-1008. PubMed ID: 34117747
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Accurate and efficient detection of gene fusions from RNA sequencing data.
    Uhrig S; Ellermann J; Walther T; Burkhardt P; Fröhlich M; Hutter B; Toprak UH; Neumann O; Stenzinger A; Scholl C; Fröhling S; Brors B
    Genome Res; 2021 Mar; 31(3):448-460. PubMed ID: 33441414
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.